During a Case-Based Roundtable® event, Jean A. Yared, MD, moderated a discussion on the approach to CAR T-cell therapy for a ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing ...

Drug coverage for four drugs used to treat some rare diseases was announced in Fredericton on Wednesday under a $32-million ...

BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or the "Company") highlights the potential for its DPXtm non-systemic immune educating platform to address the inherent limitations of lipid ...

Arvinas Holding Company (ARVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

Wealth Advisors LLC raised its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 3.9% during the 4th quarter, ...

Claro Advisors LLC purchased a new stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & ...

The inflammasome, a group of immune proteins, prevents early cancer development by controlling stem cell proliferation, ...

"Congratulations!" "Er, thanks — what for?" "For beating cancer!" Congratulations are certainly due but not to me. I was just ...

The announcement is part of the National Strategy for Drugs for Rare Diseases, which has committed up to $1.4 billion for ...

According to a recent report from Future Market Insights, the global allogeneic T-cell therapies market was valued at USD 1.1 ...